In Q4 2025, Ceribell generated total revenue of $24.8 million, a 34% increase from $18.5 million a year earlier, with product revenue up 33% to $18.8 million and subscription revenue up 37% to $6.0 million. Full-year revenue reached $89.1 million, up 36% from $65.4 million, driven by expansion into 647 active accounts.

Gross profit in Q4 was $21.6 million, yielding an 87% margin, while full-year gross margin stood at 88% on $78.3 million profit. Operating expenses rose 24% to $36.2 million in Q4 and 42% to $136.7 million for the year, reflecting investments in commercial expansion, headcount growth and public company operations. Net loss in Q4 was $13.5 million ($0.36 per share) versus $12.6 million ($0.40), and full-year net loss was $53.4 million ($1.46 per share).

Ceribell received FDA 510(k) clearance for its continuous delirium monitoring solution and for use of its Clarity algorithm in pre-term neonates, becoming the first FDA-cleared seizure detection algorithm spanning neonates through adults. The company also secured FDA Breakthrough Device Designation for its large vessel occlusion (LVO) stroke detection and monitoring solution, positioning it to address a potential $1.5 billion market opportunity.

Ceribell projects 2026 revenue between $111 million and $115 million, reflecting 25%–29% growth. As of December 31, 2025, the company held $159.3 million in cash, cash equivalents and marketable securities to support ongoing research, commercial expansion and regulatory initiatives.